Special Issue

Contrast Agents for Imaging: Past, Present and Future

Message from the Guest Editors

According to the World Health Organization (WHO), cancer is one of the major causes of mortality worldwide, with 18 million new cases (10 million deaths) in 2018, and is projected to account for 17 million deaths annually by 2030. There are several strategies that can be used to overcome this huge problem, namely, the development of imaging techniques and contrast agents with greater resolution and sensitivity, aiming at early detection. This Special Issue on "Contrast Agents" for Imaging: Past, Present and Future" invites researchers to contribute with original research or review papers related to the design/development of contrast agents for Imaging. This Special Issue intends to summarize the state of the art and the latest findings in the contrast agent field, as well as to propose future directions for this area. Contributions may include the synthesis of new contrast agents, characterization, its evaluation for the imaging technique, and in vitro and in vivo studies.

Guest Editors

Dr. Sara Pinto

Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal

Prof. Dr. Mariette M. Pereira

Department of Chemistry, University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions

closed (30 June 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/90825

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

